跳转至内容
Merck
所有图片(2)

主要文件

SML0700

Sigma-Aldrich

FTY720

FTY720

≥98% (HPLC), powder, sphingosine 1-phosphate receptor modulator

别名:

2-氨基-2- [2-(4-辛基-苯基)-乙基]-丙烷-1,3-二醇 盐酸盐, 芬戈莫德 盐酸盐

登录查看公司和协议定价

选择尺寸

5 MG
$107.00
25 MG
$437.00

$107.00


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
5 MG
$107.00
25 MG
$437.00

About This Item

经验公式(希尔记法):
C19H33NO2 · HCl
分子量:
343.93
分類程式碼代碼:
12352211
NACRES:
NA.77

$107.00


请联系客服了解存货情况

获取大包装报价

产品名称

FTY720, ≥98% (HPLC)

品質等級

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

water: 10 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

Cl.NC(CO)(CO)CCc1ccc(cc1)CCCCCCCC

InChI

1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H

InChI 密鑰

SWZTYAVBMYWFGS-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

應用

FTY720已被用作一种免疫调节剂,可用于研究其对P19C5干细胞的体外原肠胚模型的影响。[1][2]它还可用于确定其延长角膜移植存活的功效。[3]通过使用5-溴-2-脱氧尿苷掺入测定、神经球形成试验和蛋白质印迹分析,FTY720已被用于研究其对培养的胚胎海马神经干细胞(NSCs)的增殖和分化的影响。[4]

生化/生理作用

FTY720是一种免疫调节药物以及1-磷酸鞘氨醇(S1P)受体的调节剂。 鞘氨醇激酶对FTY270的磷酸化可导致S1P1R的内化,从而螯合淋巴结中的淋巴细胞,阻止它们参与自身免疫反应。 临床上,它已被批准用于治疗多发性硬化症(MS)。研究显示其可通过抑制S1PR阻断和逆转紫杉醇诱导的化疗诱导的周围神经病变(CIPN),并可抑制小鼠脑海马中组蛋白脱乙酰酶的活性,从而调节记忆。
FTY720是一种免疫调节药物,可作为鞘氨醇-1-磷酸(S1P)受体的调节剂。

象形圖

Health hazard

訊號詞

Warning

危險聲明

防範說明

危險分類

STOT RE 2

標靶器官

Immune system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Mehling et al.
Neurology, 76(8 Suppl 3), S20-S27 (2011-02-26)
The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)).
Goeril Karlsson et al.
Neurology, 82(8), 674-680 (2014-01-28)
To report outcomes of pregnancies that occurred during the fingolimod clinical development program. Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined
The sphingosine-1-phosphate analogue, FTY-720, promotes the proliferation of embryonic neural stem cells, enhances hippocampal neurogenesis and learning and memory abilities in adult mice.
Sun Y, et al.
British Journal of Pharmacology, 173(18), 2793-2807 (2016)
M Kipp et al.
Multiple sclerosis (Houndmills, Basingstoke, England), 18(3), 258-263 (2012-03-03)
FTY720 (fingolimod; Gilenya®), a sphingosine 1-phosphate (S1P) receptor modulator, is the first oral disease-modifying therapy to be approved for the treatment of relapsing-remitting multiple sclerosis. FTY720 is rapidly converted in vivo to the active S-fingolimod-phosphate, which binds to S1P receptors.
Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis.
Groh J, et al.
Molecular Therapy, 25(8), 1889-1899 (2017)

商品

Discover Bioactive Small Molecules for Lipid Signaling Research

Questions

  1. What is the solubility of SML0700, FTY720 in PBS?

    1 answer
    1. SML0700, FTY720 is soluble in water but not very soluble in PBS. The solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Other solvents for this item include DMF, DMSO, Ethanol, and Ethanol:PBS (pH 7.2) (1:1).

      Helpful?

Reviews

Active Filters

  1. 1 Ratings-Only Review

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门